A Study of NX-019 in Patients with Advanced, Epidermal Growth Factor Receptor (EGFR) Mutant Cancer

NCT ID: NCT05514496

Last Updated: 2025-03-11

Basic Information

• Recruitment Status: ACTIVE_NOT_RECRUITING
• Clinical Phase: PHASE1
• Total Enrollment: 258 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2022-10-05
• Study Completion Date: 2025-12-01

Brief Summary

This is a 2-part, first-in-human, open-label study to determine the safety and tolerability of NX-019 and preliminary efficacy in patients with locally advanced or metastatic epidermal growth factor receptor (EGFR)-mutant cancer.

Detailed Description

Part 1: The primary objective of Part 1 of this study is to evaluate the safety and tolerability of NX-019 and to determine the maximum tolerated dose (MTD)/Recommended Expansion Dose(s) (REDs).

Part 2: The primary objective of Part 2 of this study is to confirm the safety and tolerability of NX-019 at the REDs and, for each expansion cohort, the preliminary evidence of efficacy as measured by objective response rate (ORR).

Conditions

EGFR Mutation-Related Tumors

Study Design

• Allocation Method: NON_RANDOMIZED
• Intervention Model: SEQUENTIAL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

Part 1: NX-019 Dose Escalation

Patients will be treated with NX-019 in multiple ascending cohorts.

Group Type: EXPERIMENTAL

NX-019

Intervention Type: DRUG

NX-019 will be administered orally.

Part 2: NX-019 Dose Expansion

Patients will be treated with the REDs of NX-019 as determined in Part 1.

Group Type: EXPERIMENTAL

NX-019

Intervention Type: DRUG

NX-019 will be administered orally.

Interventions

NX-019

NX-019 will be administered orally.

Intervention Type: DRUG

Eligibility Criteria

Inclusion Criteria

• Histologically confirmed, locally advanced, or metastatic EGFR-mutant cancer and has progressed on or are intolerant to all standard therapy.
• Patients with non-small cell lung cancer (NSCLC) harboring a mutation that is sensitive to osimertinib must have received osimertinib prior to enrollment.
• Measurable disease per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 (evaluable disease acceptable for dose escalation part of study).
• ≥18 years of age (or age of consent in in accordance with local law).
• Life expectancy ≥3 months.
• Adequate organ and bone marrow function.
• All patients will have a baseline magnetic resonance imaging (MRI) of the brain.
• Resolution of any clinically significant toxic effects of prior therapy to Grade 0 or 1 according to the National Cancer Institute CTCAE v5.0 (exception of alopecia and Grade 2 peripheral neuropathy).
• Eastern Cooperative Oncology Group (ECOG) performance status of ≤2.
• Willingness of men and women of reproductive potential to observe conventional and effective birth control methods with failure rates of <1% for the duration of treatment and for 6 months following the last dose of study treatment.
• A negative serum pregnancy test at Screening and a negative (serum or urine) pregnancy test within 72 hours before the first dose of study drug (female patients of childbearing potential only).
• Willing and able to give informed consent and comply with protocol requirements for the duration of the study.

Expansion Cohort 1:

• Patients with NSCLC with EGFR exon 19 deletions or exon 21 L858R mutations who have progressed on or after prior EGFR TKI therapy.

Expansion Cohort 2:

• Patients with NSCLC with EGFR ex20ins mutations, who are not suitable for, or are unwilling to receive available ex20ins mutation targeted therapy.

Expansion Cohort 3:

• Patients with NSCLC with EGFR mutations for which there is no current targeted therapy, (i.e., exclusion of exon 19, exon 21 L858R, and ex20ins mutation).

Exclusion Criteria

Patients who meet any of the following criteria will be excluded from participation in the study:

• Known C797X EGFR mutations or 1 or more known secondary drivers of disease.
• Disease requiring immediate palliative treatment with surgery or radiation therapy.
• Requirement for greater than 4 mg/day of dexamethasone (or equivalent) for management of CNS metastases.
• Received systemic anticancer chemotherapy, targeted agents, antibody therapy for cancer, immunotherapy for cancer, hormonal therapy or an investigational agent within 2 weeks or 5 half-lives (whichever is shorter) prior to start of study drug treatment.
• Major surgery within 3 weeks prior to start of study drug treatment.
• Radiation therapy within 4 weeks prior to start of study drug treatment.
• Severe or unstable cardiac conditions within 6 months prior to starting study drug treatment.
• Severe or unstable medical condition including uncontrolled diabetes or unstable psychiatric condition.
• Dependent on contact lenses (unable to wear eyeglasses) and unable to comply with ophthalmic guidance.
• History of interstitial lung disease, radiation pneumonitis which required systemic steroid therapy, or other significant lung disease.
• Another active malignancy within the previous 2 years except for localized cancers that are not related to the current cancer being treated, are considered cured, and, in the opinion of the Investigator, present a low risk of recurrence.
• Active infection requiring systemic therapy.
• Known human immunodeficiency virus (HIV), hepatitis B virus (HBV) (i.e., hepatitis B surface antigen-positive), or hepatitis C virus (HCV) (i.e., detectable HCV ribonucleic acid [RNA]).
• Active gastrointestinal disease (e.g., Crohn's disease, ulcerative colitis, or short gut syndrome) or conditions that may impact drug absorption.
• Pregnant or breastfeeding.
• Is using a strong CYP3A inhibitor or inducer, and cannot refrain from use from 7 days prior to the first dose and throughout the study.
• Is using a proton pump inhibitor and cannot refrain from use from 7 days prior to the first dose and throughout the study.
• Is using a sensitive substrate of P-gp with a narrow therapeutic window (e.g. digoxin).
• Any other condition, including significant skin or nail disease, that in the opinion of the Investigator would place the patient at an unacceptable risk or cause the patient to be unlikely to fully participate or comply with study procedures.

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Nalo Therapeutics Inc.

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Locations

City of Hope Comprehensive Cancer Center - Duarte

Duarte, California, United States

City of Hope - Seacliff

Huntington Beach, California, United States

City of Hope Orange County Lennar Foundation Cancer Center

Irvine, California, United States

HealthPartners Frauenshuh Cancer Center

Saint Louis Park, Minnesota, United States

HealthPartners Cancer Center at Regions Hospital

Saint Paul, Minnesota, United States

University Of Virginia Comprehensive Cancer Center

Charlottesville, Virginia, United States

NEXT Virginia

Fairfax, Virginia, United States

Seoul National University Hospital

Seoul, , South Korea

Severance Hospital

Seoul, , South Korea

Asan Medical Center

Seoul, , South Korea

Samsung Medical Center

Seoul, , South Korea

National Taiwan University Cancer Center

Taipei City, Taipei, Taiwan

Countries

United States; South Korea; Taiwan

Other Identifiers

NT019-101

Identifier Type: -

Identifier Source: org_study_id